ArticleNature2025
ACLY inhibition promotes tumour immunity and suppresses liver cancer.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Emerging roles of ATP citrate lyase in kidney diseases: from pathogenic driver to therapeutic target.Renal failure · 2026Review
- New insights into the ACLY-mediated metabolic and epigenetic interplay in macrophages.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- Epigenomic Remodeling by Lipid Metabolism: A Cross-Disease Perspective on Cancer and Brain Disorders.Genes · 2026Review
- Acetyl-CoA-dependent processes are preferentially supported by local metabolite synthesis.Science advances · 2026Article
- GSK3β and Plk1 sequentially phosphorylate ATP-citrate lyase to promote homologous recombination.Science advances · 2026Article
- Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer.Signal transduction and targeted therapy · 2026Review
- Advances in Lipid Metabolism Reprogramming in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2026Review
- Absolute quantitative proteomics guides patient-stratified drug repurposing in clear cell and papillary renal cell carcinoma.bioRxiv : the preprint server for biology · 2026Article
- Modulation of the ACLY-AMPK axis by bempedoic acid suppresses NF-κB-driven inflammation, VEGF-Notch angiogenic crosstalk, and cell-cycle progression in Solid Ehrlich Carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- ACLY alleviates cerebral ischemia/reperfusion injury by reducing oxidative stress and enhancing mitochondrial function via histone acetylation.Cell death & disease · 2026Article
- Protein modification systems as cancer biomarkers and therapeutic targets.Precision clinical medicine · 2026Review
- De Novo Lipogenesis in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Therapeutic Implications.International journal of molecular sciences · 2026Review
- The impact of lactate and lipid metabolism in microglia upon cognitive impairment following radiation-induced brain injury.Journal of translational medicine · 2026Review
- Repositioning ACLY in liver cancer: from metabolic enzyme to a regulator of antitumor immunity.Science China. Life sciences · 2026Article
- Lipid metabolism reprogramming shapes the immune landscape in the tumor microenvironment.Cellular & molecular immunology · 2026Review
- Locoregional lactate dehydrogenase inhibition potentiates therapy and overcomes treatment resistance in hepatocellular carcinoma.Hepatology (Baltimore, Md.) · 2026Article
- Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025.Cancer innovation · 2026Review
- [Advances in basic and experimental diagnostic research on liver diseases in 2025].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Reprogrammed Lipid Metabolism as a Gatekeeper of Hepatocarcinogenesis: from Enzyme Regulation to Precision Therapy.Current oncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Jaya Gautam *Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Jianhan Wu *Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-7539-3158
James S V Lally *Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Jamie D McNicolMcMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0009-0007-3650-3506
Russta FayyaziCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Elham AhmadiCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0003-0472-4615
Daniela Carmen OniciuEspervita Therapeutics, Ann Arbor, MI, USA.
Spencer HeatonEspervita Therapeutics, Ann Arbor, MI, USA.
Roger S NewtonEspervita Therapeutics, Ann Arbor, MI, USA.
Sonia RehalCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Dipankar BhattacharyaDivision of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Fiorella Di PastenaCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Binh NguyenDivision of Clinical Immunology and Allergy, McMaster Immunology Research Centre, Schroeder Allergy and Immunology Research Institute, McMaster University, Hamilton, Ontario, Canada.
Celina M ValvanoCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0009-0008-5164-4224
Logan K TownsendCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-4311-2702
Suhrid BanskotaCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0003-3183-6268
Battsetseg BatchuluunCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Maria Joy Therese JabileCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Alice PayneCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Junfeng LuCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-2640-8595
Eric M DesjardinsCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Naoto KubotaDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Evangelia E TsakiridisCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Bejal MistryCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Alex AganostopoulosCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Vanessa HoudeCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Ann DansercoerDepartment of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
Koen H G VerschuerenDepartment of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.
Savvas N SavvidesDepartment of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.ORCID 0000-0003-3420-5947
Joanne A HammillMcMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Ksenia BezverbnayaMcMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Paola MutiCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Theodoros TsakiridisCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-8675-4422
Wenting DaiDepartment of Molecular and Cellular Endocrinology, Diabetes and Metabolism Research Institute, City of Hope Medical Center, Duarte, CA, USA.
Lei JiangDepartment of Molecular and Cellular Endocrinology, Diabetes and Metabolism Research Institute, City of Hope Medical Center, Duarte, CA, USA.ORCID 0000-0002-8596-556X
Yujin HoshidaDivision of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0001-9430-1426
Mark LarchéDivision of Clinical Immunology and Allergy, McMaster Immunology Research Centre, Schroeder Allergy and Immunology Research Institute, McMaster University, Hamilton, Ontario, Canada.
Jonathan L BramsonMcMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0003-2874-6886
Scott L FriedmanDivision of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-1178-6195
Kenneth VerstraeteDepartment of Biochemistry and Microbiology, Ghent University, Ghent, Belgium.ORCID 0000-0001-6544-6458
Dongdong WangCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-6195-4428
Gregory R SteinbergCentre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, Ontario, Canada. gsteinberg@mcmaster.ca.ORCID 0000-0001-5425-8275
Funding
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7MTHE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4MTrial of Statins for Chemoprevention in Hepatocellular CarcinomaR01CA255621 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T, HOSHIDA, YUJIN · 2021 to 2025
$3.6MReverse-engineering precision liver cancer chemopreventionR01CA233794 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2019 to 2023
$3.5MHepatic stellate cells in NASH fibrosis and HCCR01DK128289 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCOTT L. FRIEDMAN · 2021 to 2026
$2.6MMolecular Prognostic Indicators in Liver Cirrhosis and CancerR01DK099558 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOSHIDA, YUJIN · 2013 to 2016
$2.6MMannose metabolism as a regulator of hepatic stellate cell activation and fibrosisR01DK121154 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CHU, JAIME C · 2020 to 2024
$2.3MEpigallocatechin gallate for prevention of lethal cirrhosis complicationsR01CA282178 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Yujin Hoshida, Amit Singal · 2023 to 2026
$1.8MNCI NIH HHS P30 CA142543NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA233794NCI NIH HHS R01 CA255621NCI NIH HHS R01 CA282178NIDDK NIH HHS R01 DK099558NIDDK NIH HHS R01 DK121154NIDDK NIH HHS R01 DK128289
Abstract
Immunosuppressive tumour microenvironments are common in cancers such as metabolic dysfunction-associated steatohepatitis (MASH)-driven hepatocellular carcinoma (HCC) (MASH-HCC)
Indexed as
ATP Citrate (pro-S)-LyaseCarcinoma, HepatocellularEnzyme InhibitorsLiver NeoplasmsAnimalsDisease Models, AnimalFemaleHepatocytesHumansLiverMaleMiceTumor MicroenvironmentATP Citrate (pro-S)-LyaseEnzyme Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.